4 articles
Novo Nordisk is exploring a direct listing on the New York Stock Exchange to replace current American depositary receipts and boost its US profile. CEO Mike Doustdar confirmed the potential move durin
Novo Nordisk CEO Mike Doustdar forecasts oral obesity drugs may comprise half the global market by 2030 as the company advances five oral treatments. Holding over 80% of new oral prescriptions, Novo a
Novo Nordisk CEO Mike Doustdar unveiled "The Novo Way" cultural strategy to regain market leadership against rival Eli Lilly in the obesity drug sector. The initiative emphasizes customer obsession as
Novo Nordisk plans to seek Chinese regulatory approval for its oral Wegovy pill very soon, CEO Mike Doustdar said. The company aims to compete with Eli Lilly in China's rapidly expanding GLP-1 market,
ChemBrief